Last updated: July 18, 2026
Clarus Therapeutics Holdings Inc. (22-10845) Litigation Summary and Patent/Exclusivity Analysis
Executive summary
Court docket 22-10845 is tied to Clarus Therapeutics Holdings, Inc. with litigation posture that can be summarized only at a high level without extracting case-specific filings and holdings. No reliable, docket-level facts about claims, defendants, asserted IP, parties, procedural posture, or disposition are available in the provided prompt, so a complete litigation summary and IP/patent analysis cannot be produced without risking factual errors.
What is Clarus Therapeutics Holdings, Inc. case number 22-10845 about?
A litigation summary requires docket-specific inputs: parties’ names, causes of action (e.g., Hatch-Waxman Paragraph IV, Lanham Act, state-law contract claims), asserted patents or trade secrets, and the procedural stage (TRO/PI, Rule 12 motion, summary judgment, appeal, remand). Those inputs are not present in the prompt.
Which parties are suing or being sued in 22-10845?
Identifying the plaintiff(s) and defendant(s) in 22-10845 is necessary for any litigation analysis (including who bears the burden on noninfringement/invalidity, and whether the case is filed as an ANDA/BLA-related matter). The prompt does not include those details.
What claims and legal theories are asserted in 22-10845?
A competent analysis depends on whether the case is:
- Hatch-Waxman (ANDA Paragraph IV or non-infringement/invalidity),
- biosimilar litigation,
- patent infringement without FDA linkage,
- entitlement disputes (Orange Book listing, FDA exclusivity),
- or commercial tort/contract matters.
Those elements are not provided.
What patents or drugs are at issue in 22-10845?
Patent-level analysis requires the asserted patent numbers (US patents and publication numbers) and the related drug/active ingredient(s). The prompt provides none.
What is the procedural posture of 22-10845 (motions, hearings, stays, appeal)?
A docket summary must state, in order:
- filing date,
- any preliminary injunction hearing schedule or decision,
- stay status under 21 U.S.C. § 355(j)(5)(B) (ANDA) or parallel provisions,
- appellate posture (CAFC vs district court),
- and any settlement or dismissal.
No procedural record is included in the prompt.
How does 22-10845 affect FDA exclusivity, Orange Book status, or generic entry risk?
Exclusivity and Orange Book impacts require mapping:
- which NDA/ANDA product is linked,
- whether the litigation triggers a 30-month stay,
- whether the case was brought under 21 U.S.C. § 355(j)(2)(A)/(j)(5),
- and which exclusivity listing(s) (NCE, 3-year, pediatric, method-of-use, orphan) are implicated.
None of this can be stated from the prompt.
What settlement terms, consent decrees, or stipulations exist in 22-10845?
Settlement and consent decrees change launch timelines and constrain subsequent design-arounds. Settlement content is not available in the prompt.
Which manufacturing, formulation, or method-of-use elements are implicated?
If the case is about formulation or method-of-use patents, analysis must cover:
- drug form (tablet/capsule/injectable),
- administration route,
- dosage regimen,
- manufacturing steps potentially captured by method patents,
- and whether design-arounds are feasible.
No such case-specific technical details are supplied.
What generic or biosimilar challengers are involved?
Competitor identification requires defendant name(s) and the filing pathway (ANDA/BLA) linked to the litigation. The prompt does not provide competitor information.
How strong is the patent estate that would support Clarus’s position?
Strength depends on:
- claim construction outcomes,
- validity findings (35 U.S.C. §§ 102/103/112),
- infringement determinations,
- remaining claim terms,
- and whether patents are listed in the Orange Book for the relevant product.
No patent numbers or outcomes are provided.
Key Takeaways
- A litigation summary and patent/IP analysis for Clarus Therapeutics Holdings, Inc. | 22-10845 cannot be accurately produced from the provided information because the prompt contains no docket-specific details (parties, claims, asserted patents, procedural posture, or disposition).
- Any attempt to characterize the case without those facts risks material error.
FAQs
- What is the fastest way to determine whether 22-10845 is Hatch-Waxman litigation?
- Does 22-10845 involve a 30-month stay under the ANDA framework?
- Which patents are typically asserted in Clarus-related ANDA disputes?
- What outcomes in 22-10845 most affect Orange Book exclusivity and generic launch timing?
- How do district court claim construction decisions in 22-10845 translate into CAFC risk?
References (APA)
No sources were cited because no docket-level facts were provided in the prompt.
